VIVIMEDLAB Share Price | Vivimed Labs Ltd Stock Analysis & Recommendation

Q: When is the next results date for Vivimed Labs Ltd?

The next results date for Vivimed Labs Ltd is scheduled for 13 March 2026.

Q: Should I buy, sell or hold Vivimed Labs Ltd?

Based on the current financial situation of Vivimed Labs Ltd, it is advisable to consider a strong sell position. The company is facing significant challenges, including a very high debt-equity ratio of 9.51 times, indicating a weak long-term fundamental strength. Additionally, the high debt to EBITDA ratio of 12.57 times suggests a low ability to service its debt obligations.Profitability is another concern, as the average return on equity stands at just 1.75%, which reflects low profitability relative to shareholders' funds. The company's performance has been flat, with no growth reported in December 2025, and it has experienced a drastic decline in profits by 386% over the past year, while the stock has generated a return of 0.00%.Given these factors, including the negative EBITDA and the risky trading conditions compared to historical valuations, it would be prudent to avoid investing in Vivimed Labs Ltd at this time.

Q: Why is Vivimed Labs Ltd falling/rising?

As of 17-Mar, Vivimed Labs Ltd's stock price is falling, currently at Rs. 6.44, which represents a decrease of Rs. 0.16 or 2.42%. The stock has been on a downward trend, having lost 9.3% over the last four days and is currently trading below its 5-day, 20-day, 50-day, 100-day, and 200-day moving averages, indicating a consistent decline in price momentum. Additionally, the stock hit a new 52-week low of Rs. 6.35 today. Investor participation has also decreased, with delivery volume falling by 36.67% compared to the 5-day average, suggesting reduced interest from investors. Over the past week, the stock has underperformed its sector by 2.7%, and year-to-date, it has plummeted by 63.47%, significantly worse than the Sensex, which has only declined by 10.74% in the same period. These factors collectively contribute to the ongoing decline in Vivimed Labs Ltd's stock price.

Q: Why is Vivimed Labs Ltd falling/rising?

As of 18-Mar, Vivimed Labs Ltd's stock price is rising, currently at Rs 6.60, reflecting an increase of Rs 0.23 or 3.61%. This upward movement comes after a period of four consecutive days of decline, indicating a potential trend reversal. Additionally, the stock has outperformed its sector by 3.34% today, which may contribute to positive investor sentiment.Despite the recent rise, it is important to note that the stock has experienced significant declines over longer periods, including a year-to-date drop of 62.56%. However, today's trading saw a notable increase in investor participation, with delivery volume rising by 190.55% compared to the five-day average, suggesting heightened interest in the stock.While the stock is currently trading below its moving averages across various time frames, the recent performance and increased trading activity may signal a shift in market perception, leading to the current rise in price.

Q: Why is Vivimed Labs Ltd falling/rising?

As of 19-Mar, Vivimed Labs Ltd's stock price is falling, currently at Rs. 6.33, which reflects a decrease of Rs. 0.27 or 4.09%. The stock has significantly underperformed in various time frames, with a decline of 9.18% over the past week and 17.79% over the past month. Year-to-date, the stock has plummeted by 64.10%, while the benchmark Sensex has only decreased by 12.92% in the same period.Today, the stock hit a new 52-week low of Rs. 6.31 and has underperformed its sector by 1.94%. Additionally, Vivimed Labs is trading below its moving averages across multiple time frames, including the 5-day, 20-day, 50-day, 100-day, and 200-day moving averages, indicating a persistent downward trend. The pharmaceuticals and drugs sector has also seen a decline of 2.13%, contributing to the negative sentiment surrounding the stock.Investor participation appears to be waning, as evidenced by a delivery volume of 89.03k on March 18, which is down 59.47% compared to the 5-day average. This drop in trading activity suggests a lack of confidence among investors, further exacerbating the stock's decline. Overall, the combination of poor performance metrics, low investor participation, and sector-wide declines are key factors contributing to the falling stock price of Vivimed Labs Ltd.

Results Declared: Vivimed Labs. has declared results on 18 Mar 2026! Click here to unlock the latest financial performance

52-Week Low: Rs.6.03 hit today

Price Point

High/Low

1Day

52 Week

Valuation

Technical

Day's Volume

CASH

1.84 lacs (-18.61%) Volume

Shareholding (Sep 2025)

FII

1.64%

Held by 5 FIIs

DII

0.12%

Held by 0 DIIs

Promoter

7.77%

When is the next results date for Vivimed Labs Ltd?

10-Mar-2026

The next results date for Vivimed Labs Ltd is 13 March 2026.

View full answer

Should I buy, sell or hold Vivimed Labs Ltd?

19-Mar-2026

Why is Vivimed Labs Ltd falling/rising?

17-Mar-2026

As of 17-Mar, Vivimed Labs Ltd's stock price is at Rs. 6.44, down 2.42%, and has hit a new 52-week low. The stock has seen a significant decline in investor interest and has underperformed its sector, with a year-to-date drop of 63.47%.

View full answer

Why is Vivimed Labs Ltd falling/rising?

18-Mar-2026

As of 18-Mar, Vivimed Labs Ltd's stock price is rising to Rs 6.60, marking a 3.61% increase after four days of decline, indicating a potential trend reversal. Despite a year-to-date drop of 62.56%, today's trading saw a significant rise in investor participation, suggesting increased interest in the stock.

View full answer

Why is Vivimed Labs Ltd falling/rising?

19-Mar-2026

As of 19-Mar, Vivimed Labs Ltd's stock price is at Rs. 6.33, reflecting a 4.09% decline. The stock has significantly underperformed, with a year-to-date drop of 64.10%, low investor participation, and trading below its moving averages, indicating a persistent downward trend.

View full answer

Why is Vivimed Labs Ltd falling/rising?

20-Mar-2026

As of 20-Mar, Vivimed Labs Ltd's stock price is Rs. 6.34, reflecting a significant decline of 64.04% year-to-date. The company faces serious financial challenges, including a high debt-to-equity ratio and drastically reduced profits, leading to its classification as a strong sell.

View full answer

Which are the latest news on Vivimed Labs.?

21-Mar-2026

Vivimed Labs Ltd Stock Falls to 52-Week Low of Rs.6.1
Vivimed Labs Ltd Stock Hits 52-Week Low at Rs.6.31

Which are the latest news on Vivimed Labs.?

22-Mar-2026

Vivimed Labs Ltd Stock Falls to 52-Week Low of Rs.6.1
Vivimed Labs Ltd Stock Hits 52-Week Low at Rs.6.31

Which are the latest news on Vivimed Labs.?

23-Mar-2026

Vivimed Labs Ltd Stock Falls to 52-Week Low of Rs.6.1
Vivimed Labs Ltd Stock Hits 52-Week Low at Rs.6.31

Compare Vivimed Labs. with Similar Stocks

Dr Reddy's Labs Guj. Inject(Ker)Torrent Pharma

Score

Click here to find our call on this stock

Strong Sell

Sell

Hold

Buy

Strong Buy

Dashboard

With HIgh Debt (Debt-Equity Ratio at 9.51 times)- the company has a Weak Long Term Fundamental Strength

Low ability to service debt as the company has a high Debt to EBITDA ratio of 12.57 times
The company has been able to generate a Return on Equity (avg) of 1.75% signifying low profitability per unit of shareholders funds

Flat results in Dec 25

Risky - Negative EBITDA

Mojo Parameters

Loading Valuation Snapshot...

Stock DNA

Industry

Pharmaceuticals & Drugs

Market cap

INR 50 Cr (Micro Cap)

P/E

NA (Loss Making)

Industry P/E

Dividend Yield

0.00%

Debt Equity

9.51

Return on Equity

-833.41%

Price to Book

1.33

Revenue and Profits:

Net Sales:

16 Cr

(Quarterly Results - Dec 2025)

Net Profit:

-17 Cr

Total Returns

Total Returns (Price + Dividend)

Dividend Yield (0%)

TimePeriod

Price Return

Dividend Return

Total Return

3 Months

-73.36%

6 Months

0.0%

1 Year

0.0%

2 Years

0.0%

3 Years

-13.68%

4 Years

-64.25%

5 Years

-65.96%

Latest dividend: 0.4 per share ex-dividend date: Sep-19-2018

Risk Adjusted Returns v/s

Returns Beta

Beta has not been calculated since enough price history is not available

News & Corporate Actions

News

Vivimed Labs Ltd Falls to 52-Week Low of Rs 6.03 as Sell-Off Deepens

Read full news article

Vivimed Labs Ltd Stock Falls to 52-Week Low of Rs.6.1

Vivimed Labs Ltd’s share price declined to a fresh 52-week low of Rs.6.1 on 20 Mar 2026, marking a significant downturn amid persistent financial headwinds and subdued market performance. The stock has underperformed its sector and broader indices despite a rising Sensex, reflecting ongoing concerns about the company’s financial health and valuation metrics.

Read full news article

Vivimed Labs Ltd Stock Hits 52-Week Low at Rs.6.31

Vivimed Labs Ltd’s share price declined sharply to a new 52-week low of Rs.6.31 on 19 Mar 2026, marking a significant drop amid broader market weakness and company-specific financial pressures.

Read full news article

Announcements

Q3 FY 2026 RESULTS

13-Mar-2026 | Source : BSE

Q3 FY 2026 RESULTS

Board Meeting Intimation for Notice Of Board Meeting

09-Mar-2026 | Source : BSE

Vivimed Labs Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 13/03/2026 inter alia to consider and approve Notice of Board meeting

Updates

16-Feb-2026 | Source : BSE

updates (additional information)

Corporate Actions

BOARD MEETING

No Upcoming Board Meetings

DIVIDEND

Vivimed Labs Ltd has declared 20% dividend, ex-date: 19 Sep 18

SPLITS

Vivimed Labs Ltd has announced 2:10 stock split, ex-date: 06 Apr 16

BONUS

No Bonus history available

RIGHTS

No Rights history available

Key Factors

Quality key factors

Factor

Value

Sales Growth (5y)

-53.40%

EBIT Growth (5y)

-421.22%

EBIT to Interest (avg)

-1.77

Debt to EBITDA (avg)

Negative Net Debt

Net Debt to Equity (avg)

9.51

Sales to Capital Employed (avg)

0.80

Tax Ratio

0.64%

Dividend Payout Ratio

Pledged Shares

14.80%

Institutional Holding

1.76%

ROCE (avg)

-0.76%

ROE (avg)

1.75%

Valuation key factors

Factor

Value

P/E Ratio

NA (Loss Making)

Industry P/E

Price to Book Value

1.33

EV to EBIT

-13.36

EV to EBITDA

-38.33

EV to Capital Employed

1.03

EV to Sales

3.94

PEG Ratio

Dividend Yield

ROCE (Latest)

-71.39%

ROE (Latest)

-833.41%

Technicals key factors

Indicator

Weekly

Monthly

MACD

Bearish

Mildly Bullish

RSI

Bearish

Bollinger Bands

Bearish

Moving Averages

Mildly Bullish (Daily)

KST

Mildly Bearish

Mildly Bullish

Dow Theory

Mildly Bearish

OBV

Mildly Bearish

No Trend

Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish Turned

Shareholding

Shareholding Snapshot : Sep 2025

Shareholding Compare (%holding)

Majority shareholders

Non Institution

Pledged Promoter Holdings

14.799

Mutual Funds

Held by 0 Schemes

FIIs

Held by 5 FIIs (1.64%)

Promoter with highest holding

Bbr Projects Private Limited (11.45%)

Highest Public shareholder

Kitara Piin 1102 (9.37%)

Individual Investors Holdings

65.18%

Financial

[
  {
    "link": "quarterly",
    "btn_text": "All Quarterly Results",
    "header": "Quarterly Results Snapshot (Standalone) - Dec'25 - QoQ",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "Not Applicable: The company has declared_date for only one period",
        "dir": 0
      },
      {
        "prefix": "Standalone Net Profit ",
        "suffix": "Not Applicable: The company has declared_date for only one period",
        "dir": 0
      }
    ],
    "table": {
      "header": [
        "Dec'25",
        "",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "11.63",
          "val2": "NA",
          "chgp": "NA",
          "chgp_class": "neutral"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "-11.22",
          "val2": "NA",
          "chgp": "NA",
          "chgp_class": "neutral"
        },
        {
          "field": "Interest",
          "val1": "0.94",
          "val2": "NA",
          "chgp": "NA",
          "chgp_class": "neutral"
        },
        {
          "field": "Exceptional Items",
          "val1": "0.00",
          "val2": "NA",
          "chgp": "NA",
          "chgp_class": "neutral"
        },
        {
          "field": "Standalone Net Profit",
          "val1": "-16.57",
          "val2": "NA",
          "chgp": "NA",
          "chgp_class": "neutral"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "-96.47%",
          "val2": "NA%",
          "chgp": "NA",
          "chgp_class": "neutral"
        }
      ]
    }
  },
  {
    "link": "half-yearly",
    "btn_text": "All Half Yearly Results",
    "header": "Half Yearly Results Snapshot (Consolidated) - Sep'22",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": " Growth in half year ended Sep 2022 is -21.15% vs -78.03% in Sep 2021",
        "dir": 1
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": " Growth in half year ended Sep 2022 is -72.57% vs -3,185.90% in Sep 2021",
        "dir": 1
      }
    ],
    "table": {
      "header": [
        "Sep'22",
        "Sep'21",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "94.33",
          "val2": "119.63",
          "chgp": "-21.15%",
          "chgp_class": "negative"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "-17.88",
          "val2": "0.31",
          "chgp": "-5,867.74%",
          "chgp_class": "negative"
        },
        {
          "field": "Interest",
          "val1": "18.17",
          "val2": "18.12",
          "chgp": "0.28%",
          "chgp_class": "negative"
        },
        {
          "field": "Exceptional Items",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "-44.23",
          "val2": "-25.63",
          "chgp": "-72.57%",
          "chgp_class": "negative"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "-18.95%",
          "val2": "0.26%",
          "chgp": "-19.21%",
          "chgp_class": "negative"
        }
      ]
    }
  },
  {
    "link": "nine-monthly",
    "btn_text": "All Nine Monthly Results",
    "header": "Nine Monthly Results Snapshot (Consolidated) - Dec'22",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in nine months ended Dec 2022 is -14.81% vs -78.58% in Dec 2021",
        "dir": 1
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in nine months ended Dec 2022 is -26.83% vs 2.03% in Dec 2021",
        "dir": -1
      }
    ],
    "table": {
      "header": [
        "Dec'22",
        "Dec'21",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "150.07",
          "val2": "176.15",
          "chgp": "-14.81%",
          "chgp_class": "negative"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "-23.01",
          "val2": "-6.98",
          "chgp": "-229.66%",
          "chgp_class": "negative"
        },
        {
          "field": "Interest",
          "val1": "27.39",
          "val2": "29.70",
          "chgp": "-7.78%",
          "chgp_class": "positive"
        },
        {
          "field": "Exceptional Items",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "-62.54",
          "val2": "-49.31",
          "chgp": "-26.83%",
          "chgp_class": "negative"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "-15.33%",
          "val2": "-3.96%",
          "chgp": "-11.37%",
          "chgp_class": "negative"
        }
      ]
    }
  },
  {
    "link": "annual",
    "btn_text": "All Annual Results",
    "header": "Annual Results Snapshot (Consolidated) - Mar'25",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in year ended Mar 2025 is -37.86% vs -21.15% in Mar 2023",
        "dir": -1
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in year ended Mar 2025 is 90.27% vs -385.63% in Mar 2023",
        "dir": 1
      }
    ],
    "table": {
      "header": [
        "Mar'25",
        "Mar'23",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "116.27",
          "val2": "187.10",
          "chgp": "-37.86%",
          "chgp_class": "negative"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "-13.05",
          "val2": "-187.30",
          "chgp": "93.03%",
          "chgp_class": "positive"
        },
        {
          "field": "Interest",
          "val1": "2.95",
          "val2": "35.90",
          "chgp": "-91.78%",
          "chgp_class": "positive"
        },
        {
          "field": "Exceptional Items",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "-31.96",
          "val2": "-328.53",
          "chgp": "90.27%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "-11.22%",
          "val2": "-100.11%",
          "chgp": "88.89%",
          "chgp_class": "positive"
        }
      ]
    }
  }
]

Quarterly Results Snapshot (Standalone) - Dec'25 - QoQ

Dec'25

Change(%)

Net Sales

11.63

Operating Profit (PBDIT) excl Other Income

-11.22

Interest

0.94

Exceptional Items

0.00

Standalone Net Profit

-16.57

Operating Profit Margin (Excl OI)

-96.47%

NA%

Values in Rs Cr.

Compare with Peers

Net Sales

Not Applicable: The company has declared_date for only one period

Standalone Net Profit

Not Applicable: The company has declared_date for only one period

All Quarterly Results

Half Yearly Results Snapshot (Consolidated) - Sep'22

Sep'22

Sep'21

Change(%)

Net Sales

94.33

119.63

-21.15%

Operating Profit (PBDIT) excl Other Income

-17.88

0.31

-5,867.74%

Interest

18.17

18.12

0.28%

Exceptional Items

0.00

Consolidate Net Profit

-44.23

-25.63

-72.57%

Operating Profit Margin (Excl OI)

-18.95%

0.26%

-19.21%

Values in Rs Cr.

Compare with Peers

Net Sales

Growth in half year ended Sep 2022 is -21.15% vs -78.03% in Sep 2021

Consolidated Net Profit

Growth in half year ended Sep 2022 is -72.57% vs -3,185.90% in Sep 2021

All Half Yearly Results

Nine Monthly Results Snapshot (Consolidated) - Dec'22

Dec'22

Dec'21

Change(%)

Net Sales

150.07

176.15

-14.81%

Operating Profit (PBDIT) excl Other Income

-23.01

-6.98

-229.66%

Interest

27.39

29.70

-7.78%

Exceptional Items

0.00

Consolidate Net Profit

-62.54

-49.31

-26.83%

Operating Profit Margin (Excl OI)

-15.33%

-3.96%

-11.37%

Values in Rs Cr.

Compare with Peers

Net Sales

YoY Growth in nine months ended Dec 2022 is -14.81% vs -78.58% in Dec 2021

Consolidated Net Profit

YoY Growth in nine months ended Dec 2022 is -26.83% vs 2.03% in Dec 2021

All Nine Monthly Results

Annual Results Snapshot (Consolidated) - Mar'25

Mar'25

Mar'23

Change(%)

Net Sales

116.27

187.10

-37.86%

Operating Profit (PBDIT) excl Other Income

-13.05

-187.30

93.03%

Interest

2.95

35.90

-91.78%

Exceptional Items

0.00

Consolidate Net Profit

-31.96

-328.53

90.27%

Operating Profit Margin (Excl OI)

-11.22%

-100.11%

88.89%

Values in Rs Cr.

Compare with Peers

Net Sales

YoY Growth in year ended Mar 2025 is -37.86% vs -21.15% in Mar 2023

Consolidated Net Profit

YoY Growth in year ended Mar 2025 is 90.27% vs -385.63% in Mar 2023

All Annual Results

Company CV

About Vivimed Labs Ltd

Vivimed Labs Ltd

Micro Cap

Pharmaceuticals & Drugs

Vivimed Labs Ltd is engaged in manufacturing of Specialty Chemicals (mainly used in Personal Care and Cosmetic Industry), Pharmaceuticals, API's and Formulations. The company has strong presence in the areas of Health & Personal Care, Contract Research and Manufacturing. The company has four subsidiary companies, namely Creative Health Care Pvt Ltd, Vivimed Holdings Ltd (Hong Kong), Vivimed Labs Europe Ltd (UK) and Vivimed Labs USA Inc.

Company Coordinates

Company Details

Plot No 78-A, Kolhar Industrial Area Bidar Karnataka : 585403

Tel: 91-8482-232045

http://www.vivimedlabs.com

yugandhar.kopparthi@vivimeslabs.com

Registrar Details

Aarthi Consultants Pvt Ltd, 1-2-285 , Domalaguda, Hyderabad